A Phase 3 interventional study of Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. and Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d. in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 52nd largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 77th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 317 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 70th largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 86 in phase 3, and was the 93rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM) with inadequate glycemic control.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d. · Drug: Metformin
Drug: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d. · Drug: Metformin
Drug page: Sitagliptin
Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54
HbA1c is measured as percent. Thus this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.
Time frame: Baseline and 54 Weeks
Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54
Change from baseline at Week 54 is defined as Week 54 minus Week 0.
Time frame: Baseline and Week 54
First patient in the 30-week extension study: 21-Sep-2007. Last patient last visit of the 30-week extension study: 23-Jan-2009; 53 study centers worldwide.
| Milestone | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. |
|---|---|---|
| Started | 164 | 153 |
| Completed | 150 | 142 |
| Not completed | 14 | 11 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Needed excluded medication | 1 | 1 |
HbA1c is measured as percent. Thus this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.
| Percent HbA1c | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. |
|---|---|---|
| Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54 | -2.37 (-2.54 to -2.19) | -1.86 (-2.04 to -1.68) |
Change from baseline at Week 54 is defined as Week 54 minus Week 0.
| mg/dL | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. |
|---|---|---|
| Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Fasting Plasma Glucose (FPG) at Week 54 | -61.3 (-66.7 to -55.9) | -52.8 (-58.4 to -47.2) |
Collected over Weeks 24 to 54 (i.e., the entire 30-week extension study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | — | 5/164 (3%) | 8/164 (4.9%) |
| Pioglitazone 45 mg q.d. | — | 3/153 (2%) | 8/153 (5.2%) |
| Event | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. |
|---|---|---|
| All Infections and InfestationsInfections and infestations | 3/164 | 2/153 |
| AppendicitisInfections and infestations | 2/164 | 0/153 |
| Gastroenteritis viralInfections and infestations | 0/164 | 1/153 |
| Pyelonephritis chronicInfections and infestations | 0/164 | 1/153 |
| All Nervous System DisordersNervous system disorders | 1/164 | 1/153 |
| Cerebrovascular accidentNervous system disorders | 0/164 | 1/153 |
| All Cardiac DisordersCardiac disorders | 1/164 | 0/153 |
| Coronary artery insufficiencyCardiac disorders | 1/164 | 0/153 |
| Lobar pneumoniaInfections and infestations | 1/164 | 0/153 |
| PresyncopeNervous system disorders | 1/164 | 0/153 |
| Event | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. |
|---|---|---|
| All Infections and InfestationsInfections and infestations | 8/164 | 8/153 |
| NasopharyngitisInfections and infestations | 8/164 | 8/153 |
| Age, Continuous(years) | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. | Total |
|---|---|---|---|
| Mean | 51.4 ± 10.0 | 52.3 ± 11.5 | 51.8 ± 10.7 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. | Total |
|---|---|---|---|
| Female | 78 | 63 | 141 |
| Male | 86 | 90 | 176 |
| Race/Ethnicity, Customized(participants) | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. | Total |
|---|---|---|---|
| White | 93 | 85 | 178 |
| Black | 7 | 3 | 10 |
| Asian | 42 | 41 | 83 |
| Other | 22 | 24 | 46 |
| Hemoglobin A1c (HbA1c)(Percent) | Sitagliptin 100 mg q.d. + Pioglitazone 45 mg q.d. | Pioglitazone 45 mg q.d. | Total |
|---|---|---|---|
| Mean | 9.4 ± 1.2 | 9.4 ± 1.2 | 9.4 ± 1.2 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Sep 2007 to primary completion in Jan 2009, 16 months.
Results were first posted in Feb 2010, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin